

Jean F P Lestingi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5926856/publications.pdf>

Version: 2024-02-01

5
papers

119
citations

2258059

3
h-index

2550090

3
g-index

5
all docs

5
docs citations

5
times ranked

126
citing authors

#	ARTICLE	IF	CITATIONS
1	Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. <i>European Urology</i> , 2021, 79, 595-604.	1.9	111
2	Totally laparoscopic ureteroneocystostomy with intracorporeal tailoring for primary obstructive megaureter. <i>Clinics</i> , 2011, 66, 177-179.	1.5	5
3	PD43-06 EXTENDED VS LIMITED PELVIC LYMPHADENECTOMY DURING RADICAL PROSTATECTOMY FOR INTERMEDIATE- AND HIGH-RISK PROSTATE CANCER: A PROSPECTIVE RANDOMIZED TRIAL.. <i>Journal of Urology</i> , 2015, 193, .	0.4	3
4	Reply to: Axel Heidenreich. Still Unanswered: The Role of Extended Pelvic Lymphadenectomy in Improving Oncological Outcomes in Prostate Cancer. <i>Eur Urol</i> 2021;79:605â€“6. <i>European Urology</i> , 2021, 79, 607-608.	1.9	0
5	Reply to Roberto Briganti, Giorgio Gandaglia, Markus Graefen, Steven Joniau, R. Jeffrey Karnes, and Francesco Montorsiâ€™s Letter to the Editor re: Jean F.P. Lestingi, Giuliano B. Guglielmetti, Quoc-Dien Trinh, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. <i>Eur Urol</i> 2021;79:595â€“604. Time for a Change? Clinically Meaningful Reasons Why We Will Continue Performin. <i>European Urology</i> , 2021, 79, e184-e185.	1.9	0